Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C.

Journal of medicinal chemistry·2026
Same author

Correction to "Combining Fundamental Kinetics and Standard Alkylation Assays to Prioritize Lead-like KRAS G12C Inhibitors".

ACS omega·2025
Same author

Fab-Induced Stabilization of an Ion Channel Receptor Enables Mechanistic Characterization of Small-Molecule Therapeutics.

Analytical chemistry·2025
Same author

Combining Fundamental Kinetics and Standard Alkylation Assays to Prioritize Lead-Like KRAS G12C Inhibitors.

ACS omega·2025
Same author

The discovery and structural basis of two distinct state-dependent inhibitors of BamA.

Nature communications·2024
Same author

Potent activity of polymyxin B is associated with long-lived super-stoichiometric accumulation mediated by weak-affinity binding to lipid A.

Nature communications·2024

Related Experiment Video

Updated: May 22, 2025

Multimodal Analytical Platform on a Multiplexed Surface Plasmon Resonance Imaging Chip for the Analysis of Extracellular Vesicle Subsets
06:12

Multimodal Analytical Platform on a Multiplexed Surface Plasmon Resonance Imaging Chip for the Analysis of Extracellular Vesicle Subsets

Published on: March 17, 2023

1.3K

Solution-Phase Kinetics of Ranibizumab Binding VEGF Using Solid-Phase Surface Plasmon Resonance.

John G Quinn1

  • 1Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, California 94080, United States.

Analytical Chemistry
|March 17, 2025
PubMed
Summary
This summary is machine-generated.

Developing effective anti-VEGF therapies like Ranibizumab requires precise kinetic binding measurements. This study introduces a novel assay to accurately determine high-affinity interactions, crucial for drug development.

More Related Videos

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

20.6K
Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.3K

Related Experiment Videos

Last Updated: May 22, 2025

Multimodal Analytical Platform on a Multiplexed Surface Plasmon Resonance Imaging Chip for the Analysis of Extracellular Vesicle Subsets
06:12

Multimodal Analytical Platform on a Multiplexed Surface Plasmon Resonance Imaging Chip for the Analysis of Extracellular Vesicle Subsets

Published on: March 17, 2023

1.3K
Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

20.6K
Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.3K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Vascular Endothelial Growth Factor (VEGF) pathway suppression is critical for treating diseases.
  • Low-abundance cytokines like VEGF require high-affinity antagonists for effective depletion.
  • Accurate kinetic binding constants are essential for developing anti-VEGF therapeutics such as Ranibizumab.

Purpose of the Study:

  • To develop and validate a reliable method for measuring kinetic binding constants of high-affinity VEGF-antagonist interactions.
  • To overcome challenges in measuring extremely high binding affinities and long residence times under near in vivo conditions.
  • To provide precise kinetic data for Ranibizumab's interaction with VEGF.

Main Methods:

  • Introduction of a mixed-phase surface plasmon resonance (SPR) assay to determine the association rate constant.
  • Utilization of an optimized "chaser" assay to determine the dissociation rate constant.
  • Conducting assays at 37°C in physiologically relevant buffer conditions to mimic in vivo environments.

Main Results:

  • Precise kinetic measurements for Ranibizumab binding to VEGF, including a residence time of 19 days and an affinity constant of 1.9 pM.
  • Demonstration that traditional equilibrium-based methods are insufficient for such high-affinity interactions.
  • Simulation-based exploration of the limitations of solution-phase assays and potential for misinterpretation.

Conclusions:

  • The developed kinetic assay method enables accurate characterization of molecular interactions with extremely high affinity and stability.
  • This approach is vital for the development of potent therapeutic molecules targeting challenging biological pathways.
  • Kinetic analysis provides a more robust method than equilibrium-based assays for understanding complex drug-target interactions.